Earlier is better when treating rheumatoid arthritis: but can we detect a window of opportunity?
Sytske Anne BergstraJoy A Van Der PolNaghmeh RiyaziYvonne P M Goekoop-RuitermanPit J S M KerstensWillem LemsThomas Wj HuizingaCornelia F AllaartPublished in: RMD open (2021)
The chance to achieve sDFR decreased gradually over time, and decreased fastest in patients starting slow-acting monotherapy. In both treatment groups, we found no evidence for a WOO within 2 years symptom duration.
Keyphrases
- rheumatoid arthritis
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- combination therapy
- peritoneal dialysis
- prognostic factors
- randomized controlled trial
- patient reported
- disease activity
- clinical trial
- ankylosing spondylitis
- open label
- interstitial lung disease
- replacement therapy